Saliva testing easier than clinician-collected nasopharyngeal swab specimens
edit 14 may -- most up to date info on this s is probably this interview from May 4th https://dot.la/coronavirus-rapid-test-curative-los-angeles-2645906983.html
Oral fluids is the technical term, which is slightly different from saliva. Our protocol involves having the person cough first, which releases virus from the upper and lower respiratory tract. Some of that is then caught in the saliva, and also viruses in the saliva. The idea is you're effectively sampling multiple sites at once, which we think gives a slight increase in the sensitivity of the testing.
Curative, offered to supply 50,000 saliva tests a week immediately, with the potential to increase this to 50,000 tests a day. On the day of the offer, 4 April, the UK had capacity to do just 15,499 tests a day and was only testing 8,651 people a day – far lower than other European nations such as Germany.
(these 2 minute do-at-home Saliva tests are much less invasive than the nasopharyngeal (back of the throat) swabs we are using here and give confirmation without supervision)
https://www.theguardian.com/world/2020/apr/29/uk-turned-down-offer-of-10000-coronavirus-tests-a-day-four-weeks-ago
===
https://www.genomeweb.com/pcr/curative-korvalabs-partner-create-high-throughput-covid-19-oral-fluid-testing-lab
Curative, KorvaLabs Partner to Create High-Throughput COVID-19 Oral Fluid Testing Lab
article gives more info
==
which made me comment
for us, as Practitioners who need to get close with Patients, and for which this present situation leaves us no guarantee of bio-security for either us or our Patients in a treatment situation, the potential of affordable saliva tests may allow a return to work at some point; where the Practitioner takes a test each day of work, and each Patient takes the same for each visit.
Accuracy, availability and price will all need to be aligned however.
We both have set ourselves as non-practicing for the foreseeable future, though we still are giving advice on the phone when requested, without making a definitive diagnosis.
Our Patient info is here
http://www.soul-trade.com/clinic/clinic/C19.htmlsome more links here
this from 10 days ago, and includes a link to a detailed pdf from the Food and Drug Administration (FDA) issuing an Emergency Use Authorization (EUA) for emergency use of the product,
https://www.airforcemag.com/saliva-based-covid-19-testing-coming-to-usaf/
pdf fact sheets on saliva tests for Patients pdf fact sheets on saliva testing for Practitioners, Healthcare providers==
however THIS
"A negative test result for this test means that SARS- CoV-2 RNA was not present in the specimen above the limit of detection. However, a negative result does not rule out COVID-19 and should not be used as the sole basis for treatment or patient management decisions. A negative result does not exclude the possibility of COVID-19.
both types of testing 'work' -- though we don't know their % accuracy as yet.
(the throat swabs tests have, last I saw, a 70% accuracy
(compared to a probable Physician diagnosis of known symptoms of maybe 90% accuracy)
Known Symptoms diagnosis will give probably a more accurate result than a positive test, but then there is little need for the test except for data suredness.
However the big gain is the ability to test asymptomatic people.
===
The proviso "negative does not mean there is not C19 present" is perhaps from the FDA Emergency License (EUA April 16th) which requires them to comply with many conditions including
"No advertising or promotional descriptive printed matter relating to the use of your product may represent or suggest that this test is safe or effective for the detection of SARS-CoV-2."
the throat swabs tests have, last I saw, a 70% accuracy
(compared to a probable Physician diagnosis of known symptoms of maybe 90% accuracy)
Again the benefits of easy saliva testing is that asymptomatic folk can show that they are +- 70% sure they have or do not have C19 at the time of testing.
EUA License
https://www.korvalabs.com/wp-content/uploads/2020/04/EUA-CKorva-CoV-letter-of-Authorization.pdf